Heat shock protein: a hot topic in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive disease of the lung parenchyma, causing significant morbidity and mortality [1, 2]. The therapeutic options in IPF are limited to only two recently approved drugs, pirfenidone and nintedanib, which have been shown to slow progression but are not able to stop or reverse the disease [3, 4]. Better pathophysiological knowledge is needed to develop new therapeutic strategies in IPF. The current …